The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer - Beyond the Abstract

The forthcoming STAMPEDE2 trial has three comparisons in metastatic hormone-sensitive prostate cancer. We aim to determine clinical practices among STAMPEDE trial investigators for access to imaging and therapeutic choices and explore their interest in participation in STAMPEDE2.



Hoda Abdel-Aty, MSc, FRCR, Clinical Research Fellow in Uro-Oncology, The Institute of Cancer Research and Royal Marsden Hospital, STAMPEDE trial MRC Clinical Trials Unit, University College London

Read the Abstract